| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Coelenterazine, a luciferin which is a light-emitting molecule, is a luminescent enzyme substrate that is used for monitoring reporter genes in BRET, ELISA and HTS techniques. It is a cell-permeable aequorin luminophore that acts as a very sensitive and specific chemiluminescent probe for the superoxide anion. Coelenterazine can also be used for detecting changes in intracellular Ca2+ in cells that have been transfected with apoaequorin cDNA. Coelenterazine also acts as a powerful antioxidant.
| ln Vitro |
P-glycoprotein-mediated efflux transport of coelenterazine was the cause of the poor bioluminescence observed in HCT-8 control cells transiently expressing Renilla luciferase (RLuc). On the other hand, strong bioluminescence is shown in HCT-8 cells that transiently produce RLuc, a condition in which shRNAi downregulates P-glycoprotein [3].
|
||
|---|---|---|---|
| ln Vivo |
After giving animals an intravenous injection of coelenterazine (2 mg/kg), which was followed by five minutes of exposure to a charge-coupled device (CCD) camera, the in vivo growth potential of HCC1806-RR was observed. Rluc activity was observed as luminosity released by tumor cells and was captured as pseudocolor images overlaying monochrome animal photos. The majority of animals also displayed metastases to the inguinal ILN in addition to exhibiting extremely high Rluc activity at the main location [4].
|
||
| Animal Protocol |
|
||
| References |
[1]. Markova SV, et al, Coelenterazine-dependent luciferases. Biochemistry (Mosc). 2015 Jun;80(6):714-32.
[2]. Lucas M, et al. Coelenterazine is a superoxide anion-sensitive chemiluminescent probe: its usefulness in the assay of respiratory burst in neutrophils. Anal Biochem. 1992 Nov 1;206(2):273-7. [3]. Pichler A, et al. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res. 2005 Jun 15;11(12):4487-94. [4]. Volk-Draper LD, et al. Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. Neoplasia. 2012 Oct;14(10):926-42 |
| Molecular Formula |
C26H21N3O3
|
|
|---|---|---|
| Molecular Weight |
423.46
|
|
| CAS # |
55779-48-1
|
|
| Related CAS # |
Coelenteramide;50611-86-4
|
|
| SMILES |
C1=CC=C(C=C1)CC2=C3N=C(C(=O)N3C=C(N2)C4=CC=C(C=C4)O)CC5=CC=C(C=C5)O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.2 mg/mL (0.47 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.2 mg/mL (0.47 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 2.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.2 mg/mL (0.47 mM) (saturation unknown) in 10% EtOH + 90% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3615 mL | 11.8075 mL | 23.6150 mL | |
| 5 mM | 0.4723 mL | 2.3615 mL | 4.7230 mL | |
| 10 mM | 0.2361 mL | 1.1807 mL | 2.3615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA